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with CSA, and the application of MIAS in “real-life” general 
practice. 
REVIEW CRITERIA
Contemporary, peer reviewed reports on minimally invasive 
mitral and tricuspid valve surgery were selected and reviewed 
for intra-operative, in-hospital, post-discharge and health eco-
nomic outcomes and references. 
THE HISTORICAL EVOLUTION OF MIAS 
In the British Medical Journal of 1898, Daniel Samways became 
the first physician to propose that rheumatic mitral valve (MV) 
stenosis be treated by surgical intervention. Sir Lauder Brunton 
subsequently developed and reported his animal model of 
trans-ventricular mitral commisurotomy in 1902,(21) which was 
clinically applied as the first successful AVV surgical operation 
by Elliot Carr Cutler and Samuel Levine in 1923.(22) The 12-year-
old patient survived for 4 years before passing away of pneu-
monia, but the poor outcomes of the subsequent 7 patients 
resulted in a procedural moratorium in 1929.(23)
The introduction of cardiopulmonary bypass in 1956 enabled 
safe intra-cardiac AVV access, with Duboist and Guiraun intro-
ducing the concepts of a trans-septal bi-atrial(24) and right atrial 
approaches(25) respectively. The visionary repair concepts of 
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INTRODUCTION
We are currently witnessing rapid evolution in the develop-
ment, marketing and utilisation of robotic,(1-3) endoscopic(4-5) 
and trans-catheter(6-9) atrioventricular valve (AVV) repair and 
replacement technology as alternatives to classic sternotomy 
access (CSA). Collectively, minimally invasive atrioventricular 
valve surgery (MIAS) is associated with signif icant learning 
curves,(10) which in the context of increasing patient age, opera-
tive risk profiles, expectations and strict quality control,(11-13) 
potentially deter upcoming centres from incorporating MIAS 
programmes that utilise videoscopic or robotic vision, modified 
instruments, perfusion and myocardial protective strategies into 
clinical practice. As a result, CSA is still considered by many as 
the standard approach for AVV disease, and subsequent reports 
have emerged that challenge the historically documented 
potential benefits associated with MIAS.(14) In addition, sceptics 
may prefer interventionist driven trans-catheter intervention 
(TCI) programmes to avoid the transitional challenges asso-
ciated with establishing MIAS programmes.(15) Various experi-
enced MIAS centres reported their routine use of MIAS for all 
isolated AVV pathology with excellent long-term results,(16-17) 
but whether their clinical outcomes can indeed be trans-
lated into general international surgical practice are not well 
defined.(18-20) This paper describes the historic evolution of 
MIAS, the contemporary clinical outcomes of MIAS compared 
We are currently witnessing rapid evolution in mini-
mally invasive and catheter-based atrioventricular valve 
interventions as acceptable alternatives to classic ster-
notomy access (CSA). Collectively, minimally invasive 
atrioventricular valve surgery (MIAS) is associated with 
signifi cant learning curves and its routine application is 
met with varying degrees of enthusiasm in view of strict 
quality control, clinical governance and outcome 
reporting. Whether the reported potential benefi ts and 
comparable effi cacy across a range of long-term out-
come measures reported by experienced MIAS centres 
can be translated into general international surgical 
practice, are not well defi ned. This paper describes the 
historic evolution of MIAS, the contemporary clinical 
outcomes of MIAS compared with CSA, and the appli-














MV regurgitation were proposed and refined by Davila,(26) 
Nichols,(27) Kay,(28) Carpentier,(29) McGoon(30) and many 
others.(31)
Navia and Gosgrove(32) were the first to report the concept and 
outcomes of a non-sternotomy, parasternal MV approach in 25 
patients in 1996. There were no hospital deaths, reoperations 
for bleeding, embolic complications or wound infection. Cohn 
and his group also described their similar findings with this 
approach in 43 patients.(33)
The reported success of laparoscopy in general surgery resulted 
in the application and development of video assisted thoracic 
surgery, which provided Alain Carpentier and his team with the 
opportunity to perform the first video-assisted, right mini-
thoracotomy MV-repair using ventricular fibrillation in 1996,(34) 
which subsequently provided the platform for various centres 
to refine and further develop MIAS.
Port Access™ surgery (PAS), which consists of peripheral 
cardiopulmonary bypass (CPB), guidewire directed anterograde 
endo-aortic balloon occlusion (EABO), venting, cardioplegia 
delivery and videoscopic guidance of routine AVV procedures 
through a 4cm right antero-lateral working, was initially 
developed by Heartport, Inc. (Redwood City, CA, USA) in 
1994, and was introduced by Stevens and colleagues as a 
surgical method for performing bypass grafting.(35)
The teams of Frederick Mohr,(36) Hugo Vanermen(37-38) and 
others(39-40) refined and incorporated PAS techniques into their 
routine MIAS clinical practice and reported the significant 
potential benefits in their extensive series. As an alternative 
to EABO, direct aortic clamping (DAC) was introduced 
by Angouras and Michler(41) and further developed by 
Chitwood.(42-44)
Recent developments in MIAS access include the introduction 
of a right vertical infra-axillary thoracotomy(45) and a peri-arealor 
incision approach(46) – with excellent results. 
Carpentier performed the first completely robotic MV pro-
cedure using the Da Vinci Surgical System (Intuitive Surgical, Inc. 
Sunnyvale, California, USA),(46) with various international groups 
now performing robotic AVV surgery as a routine with excellent 
reported outcomes.(47-48)
CONTEMPORARY CLINICAL OUTCOMES OF 
MIAS COMPARED WITH CSA
Cardiopulmonary bypass, ischaemic and 
procedure times
The pathophysiological and inflammatory effects of CPB and 
cardioplegic arrest for CSA and MIAS are well described.(49) 
Various reports suggest that MIAS is associated with up to 15% 
longer CPB , ischaemic and procedure times compared to 
CSA for both simple and complex AVV surgical proce-
dures.(50-61) The transition to using single shaft instruments 
through limited working space and other technical factors are 
reported as possible contributing factors in the early experi-
ence.(62-63)
Success of complex repair and replacement 
procedures
The group from Aalst reported their MIAS series of 2 872 
patients,(64) of which 2 183 (76.0%), 54 (1.9%) and 635 (22.1%) 
underwent isolated MV, isolated TV and combined MV and 
TV procedures. MV-repair was achieved in 96.4% (n=1822 
of 1891) of primary annular dilatation and degenerative valves 
and constituted 81.7% (n=2866) of all MIAS procedures 
(n=3507). Other groups also reported excellent MIAS repair 
results for simple and complex AVV procedures,(17) which 
can also be achieved in the early learning curve.(62-63) Various 
reports suggest no signif icant difference in the success of 
simple or complex AVV procedures whether performed by 
MIAS or CSA.(57,65)
Vascular complications
Most MIAS reports utilise peripheral retrograde CPB and obtain 
safe cardioplegic arrest by either EBAO or DAC.(46) For PAS, 
the group from Aalst reported an incidence of 0.4% for aortic 
dissection, of which the majority occurred during the initial 
learning curve.(64) Compared with CSA, various conflicting 
reports suggest that MIAS is associated with increased central 
aortic or major vascular injury risk.(57,59-61) However, refine-
ments in pre-operative aorto-iliac-axis evaluation strategies, 
cardiopulmonary bypass techniques,(66-67) the acquisition of 
guidewire skills and the application of TEE guided cannulation 
and EABO placement techniques(68) significantly decrease the 
risks of vascular injuries.(69) In addition, it appears that EABO is 
associated with less bleeding and vascular injury risks compared 
with DAC.(70-73) 
Conversion to classic sternotomy due to adverse 
MIAS events and its impact on clinical outcome
The incidence of MIAS conversion to CSA due to adverse intra-
operative events ranges considerably, with experienced centres 
reporting an incidence of 3.0%(64) - 3.7%.(17) The group from 
Aalst suggested an increased mortality associated with con-
version during PAS(64) and also reported their individual con-
version rates in the context of complex isolated AVV endo-
carditis (9.1%),(74) redo-PAS after previous PAS (19.2%),(75) 
difficult access congenital chest wall deformities (0%),(76) ex-
treme obesity (0%),(77) post-cardiac transplantation (0%)(78) and 
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hypertrophic obstructive cardiomyopathy with associated AVV 
disease (0%). 
Neurological events
Seeburger and his team observed postoperative neurological 
impairment in 3.1% of their MIAS series,(17) of which 2.1% and 
1.0% were classified as minor and major neurological events 
(NE) respectively. Various studies report no difference in 
NE,(49,56) transient neuropathy(53) or permanent NE(65) incidence 
between MIAS and CSA, while isolated reports of a decreased 
NE incidence following MIAS are also documented.(17,44) How-
ever, the recent Society of Thoracic Surgeons-Adult Cardiac 
Surgical Database (STS-ACSD) report,(61) supported by the 
Consensus Statement of the International Society of Mini-
mally Invasive Coronary Surgery (ISMICS) 2010(79) and other 
reports,(55-57,59-60) suggest that MIAS does indeed increase NE 
risk by 0.9% compared to CSA. Retrograde femoral cannula-
tion was not considered to be an independent predictor of NE. 
In addition to pre-operative vascular screening, refinements in 
de-airing techniques under TEE guidance and operative field 
CO2 flooding resulted in improved neurological outcomes.(79) 
The team from Aalst reported a NE incidence of 1.2% for 
their PAS series of 2 872 patients.(64) MIAS strategies that utilise 
antegrade perfusion have low NE risk and excellent outcomes. 
Recent multi-institutional reports suggest no significant differ-
ence in NE between EABO and DAC.(70-73)
Cardiac complications
Various studies compared cardiac outcomes between MIAS 
and CSA and did not identify any significant difference in the 
incidence of peri-operative myocardial infarction, low cardiac 
output syndrome, tamponade or inotropic requirements.(52-53, 57) 
For PAS, the group from Aalst reported their incidence of 
cardiac death (0.2%), acute myocardial infarction (0.7%) and 
low cardiac output syndrome (1.0%) in their series of 2 872 
patients.(64) 
A 10% incidence of post-operative atrial fibrillation (POAF) 
was reported for PAS in the PAIR registry, which is lower than 
CSA reports.(80) Mihos suggested that MIAS for isolated valve 
surgery reduces postoperative AF and resource use when 
compared with CSA.(81) Dogan(52) and Chitwood(44) suggested 
no difference in permanent post-operative pacemaker require-
ments between MIAS and CSA.
Post-operative bleeding and transfusion 
requirements
Extensive post-operative transfusions (POT) and re-exploration 
for bleeding (RE) are associated with increased mortality and 
morbidities.(82) Dogan and his colleagues reported significant 
decrease in chest drain output in MIAS compared to CSA,(52) 
which was reconfirmed by Glower(56) and other comparative 
reports.(53-55)
It is suggested that the packed red cell units transfused are less 
with MIAS compared with CSA,(53-55) but the percentage of 
patients transfused is similar.(52-55,61) Various studies also confirm 
a significant reduction in RE for bleeding with MIAS compared 
to CSA,(65,83-85) with the group from Leipzig reporting their 
RE rate of 5.1%.(17)
Respiratory morbidities
Comparative reports identif ied no signif icant difference 
between MIAS and CSA with regard to the development of 
post-operative pneumonia, pneumothorax, pleural effusion or 
other pulmonary complications(86) and it is suggested that ven-
tilation time and subsequent intensive care stay, is significantly 
reduced with MIAS.(55-60)
Gastro-intestinal events
Comparative reports identif ied no signif icant difference 
between MIAS and CSA with regard to the development of 
post-operative gastro-intestinal events.(44, 53)
Renal dysfunction
McCreath and his colleagues(87) observed a highly significant 
independent association between surgical approach and renal 
function, indicating a greater risk of acute renal injury in CSA 
compared to MIAS performed by PAS, and suggested that 
PAS may be preferable to conventional methods for patients 
with high renal risk. Other comparative reports however, iden-
tified no significant difference in post-operative renal failure 
between MIAS and CSA.(57,61)
Wound infection
In a comparative report by Grossi and his colleagues, wound 
infection occurred in 0.9% and 5.7% of MIAS and CSA patients 
respectively, which increased to 1.8% for MIAS and 7.7% for 
CSA in the elderly.(88) Felger, however, reported no significant 
difference.(53) Interestingly, the risk of developing mediastinitis(57) 
and wound dehiscence(59) is reported to be the same for 
MIAS and CSA. The impact and potential benefit of MIAS in 
immune-suppressed patients with AVV disease is not yet 
reported and may indicate a potential wound healing advan-
tage compared with CSA in developing countries. 
Duration of hospital stay
It is suggested that MIAS is associated with decreased intensive 













to CSA.(89-92) However, in-hospital stabilisation of anti-coagu-
lation regimes and completion of a 6-week antibiotic course in 
cases of infective endocarditis, does not reflect the isolated 
impact on hospitalisation of MIAS.(74-78) 
In-hospital mortality
Contemporary reports do not suggest a significant all-cause in-
hospital mortality difference between MIAS and CSA(52-63) or 
EBAO and DAC.(70-73) The group from Aalst reported a peri-
operative mortality of 2.6% for their PAS series.(64) 
Post-discharge survival
Limited comparative reports on long term risk of all-cause 
mortality between MIAS and CSA are available and do not 
identify a significant 1- and 3-year survival difference.(45) The 
group from Aalst reported the intermediate- and long-term 
PAS survival in the context of infective endocarditis (mean 63.2 
± 42.5 months, 69.4% at 10 years),(74) extreme obesity (mean 
39.4 ± 88.4 months, 100%),(76) left ventricle outflow tract 
resection and AVV surgery (mean 49.7 ± 30.0, 100%) and 
redo-PAS after previous PAS (mean 48.3 ± 39.2, 95.8% at 
5 years).(75) 
Freedom from readmission and reintervention
No significant difference between MIAS and CSA readmission 
within 30 days, risk of endocarditis or recurrence or need for 
valve related re-intervention are reported.(44,57,59)
Quality of life and patient satisfaction
Compared with CSA, small thoracic incisions are associated 
with less pain, discomfort, and postoperative analgesic require-
ments.(33,53) The group from Aalst suggested that more than 
98% of the patients were extremely pleased with the cosmetic 
result of PAS, with 42% reporting an invisible scar, 93% 
favourably assessing procedure-related pain and 34% fully 
recovered within 4 weeks.(4,16) Faster recovery of patients 
undergoing MIAS compared to CSA was demonstrated by 
Glower and his colleagues(56) and it is also reported that patients 
undergoing MIAS as their second procedure all perceived a 
faster and less painful recovery than their original CSA,(53) with 
a small but significant decrease in NYHA class after 1 year in 
favour of MIAS compared to CSA.(57-65) The impact of MIAS 
specific to young patients and rapid recovery are not yet defined 
and may offer a potential advantage in return to normal duty 
and productivity in both high-income and low- and middle-
income countries compared to CSA.
Healthcare economic implications of MIAS 
and CSA
Comprehensive cost-effectiveness analysis of the incremental 
costs and benefits of MIAS compared to CSA are limited. Atluri 
and his colleagues demonstrated no difference in total cost 
(operative and postoperative) between MIAS and CSA(93) and 
concluded that MIAS can be performed with overall equivalent 
cost and shorter hospital stay relative to CSA, as the greater 
operative cost is offset by shorter intensive care unit and 
hospital stays. Santana demonstrated that MIAS resulted in 
significant reductions in costs of cardiac imaging and laboratory 
tests, lower use of blood products, fewer peri-operative 
infections, faster recovery, shorter hospital length of stay, fewer 
requirements for rehabilitation and lower readmission rates in 
the following post-operative year, and concluded that MIAS is 
safe, effective and significantly more cost-effective than CSA.(94) 
Grossi suggested that MIAS provides similar mortality, less 
morbidity, fewer infections, shorter stay, and significant cost 
savings during primary admission compared to CSA, which 
translate into additional institutional cost savings.(95) The limited 
healthcare resources in developing countries may benefit from 
MIAS and further investigations are warranted.
APPLICATION OF MIAS IN GENERAL 
SURGICAL PRACTICE – OVERCOMING THE 
LEARNING CURVE 
Holzney and his colleagues(63) assessed the individual MIAS 
learning process from 3 895 operations performed by 17 
surgeons by analysing operation time and complication rates 
using sequential probability cumulative sum failure analysis. 
They identified the typical number of operations to overcome 
the learning curve as ranging between 75 and 125 procedures, 
and further suggested that more than 1 procedure per week is 
required to maintain acceptable results. In addition, they 
reported that the Individual learning curves varied markedly, 
proving the need for good monitoring or mentoring in the 
initial phase.
De Praetere and his colleagues from Leuven(62) assessed the 
MIAS learning curve by using a logarithmic curve-fit regression 
analysis of the CPB times, procedure complexity and the 
number of concomitant procedures. They reported the learning 
curve to be 30 procedures, with a significant reduction in aortic 
cross-clamp time before and after the end of the learning curve. 
The complexity of AVV reconstruction gradually increased and 
proportion of mitral valve replacements decreased by gradually 
expanding MIAS indications. They concluded that the transition 
from CSA to MIAS could safely be introduced into practice 
without mortality, longer intensive care or hospitalisation. 
Hunter reported a systematic approach on how to initiate a 
MIAS programme(96) and identified techniques of AVV repair, 
TEE-guided cannulation, incisions, instruments, visualisation, 
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aortic occlusion and CPB strategies as seven key aspects to 
master during the learning curve. He also emphasised the 
principles of systems awareness, teamwork, communication, 
ownership and leadership – all of which are paramount to 
performing safe and effective MIAS. 
Murzi(97) applied control charts (CUSUM curves) to monitor 
individual MIAS surgeon outcomes, with a predetermined 
acceptable failure rate, alert and alarm lines and clear procedure 
failure definitions. They identif ied signif icant inter-surgeon 
learning curve variation and concluded that the transition 
toward MIAS can be performed with low morbidity and 
mortality. 
CONCLUSION
CSA for AVV disease is well established, but its role in 
contemporary clinical practice are continuously being redefined 
by rapid evolution in trans-catheter and MIAS technology, 
patient preference and industry-driven marketing. However, 
the routine application of MIAS is met with varying degrees of 
enthusiasm in view of learning curves, strict quality control, 
clinical governance and outcome reporting. It is therefore 
imperative that contemporary international MIAS outcomes 
are meticulously evaluated for evidence of well-defined patient 
and healthcare economic benefits – before adopting these 
techniques into clinical practice. This review confirms the 
historically reported potential benefits of MIAS compared with 
CSA and comparable efficacy across a range of long-term 
efficacy measures such as freedom from reoperation and long-
term survival. Surgeons should be encouraged to adopt and 
apply MIAS in an exciting era of progressive trans-catheter 
intervention preference, whether in a first- or third-world 
clinical context.
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